5'-Cytidylic acid Clinical Trials

Size	Price	Qty
25mg	USD 97

Clinical Trials

Several clinical trials evaluate 5'-Cytidylic acid across gynecologic malignancies, renal conditions, and psychiatric disorders such as major depressive disorder and generalized anxiety disorder. Conducted by governmental, academic, and clinical groups—including the National Cancer Institute, the Gynecologic Oncology Group, Maastricht University Medical Center, and CONICET Argentina—these protocols are classified under undefined phases or designated as phase not applicable. Currently, recruitment statuses across these studies are documented as either withdrawn or not yet recruiting.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01199250	Not yet recruiting	Lynch Syndrome\|Recurrent Uterine Corpus Carcinoma\|Stage I Uterine Corpus Cancer\|Stage II Uterine Corpus Cancer\|Stage III Uterine Corpus Cancer\|Stage IV Uterine Corpus Cancer	Gynecologic Oncology Group\|National Cancer Institute (NCI)\|GOG Foundation	2100-01	--
NCT04598516	Withdrawn	Acute Kidney Injury (Nontraumatic)\|Contrast-induced Nephropathy\|Renal Insufficiency	Maastricht University Medical Center	2097-11-01	--
NCT05118594	Not yet recruiting	Major Depressive Disorder\|Dysthymic Disorder\|Specific Phobia\|Social Anxiety Disorder\|Panic Disorder\|Agoraphobia\|Generalized Anxiety Disorder	National Council of Scientific and Technical Research Argentina	2026-02	Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the 5'-Cytidylic acid product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a essential pyrimidine nucleotide monomer, 5'-cytidylic acid serves as a substrate for RNA polymerases and cytidylyltransferases, driving intracellular nucleic acid transcription and phospholipid membrane biosynthesis. By replenishing essential nucleotide pools and supporting cellular structural integrity, it sustains cell viability and tissue metabolic homeostasis, providing functional relevance to clinical investigations in renal injury, uterine carcinomas, and neuropsychiatric disorders.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).